During Monday’s Afternoon trade, Shares of Uranium Energy Corp. (NYSEMKT:UEC), surged 24.44% to $2.24.
Uranium Energy Corp., is happy to declare that the Company is to be added to the Russell 3000® Index and the Russell Global® Index at the conclusion of the annual reconstitution of the Russell indexes on June 26, 2015, according to the latest list of additions as posted June 19, 2015 on FTSE Russell’s website at: http://www.russell.com/indexes/americas/tools-resources/reconstitution/additions-deletions.page
Uranium Energy Corp. engages in the exploration, extraction, and processing of uranium concentrates on projects located in the United States and the Republic of Paraguay. As of July 31, 2014, it had mineral rights in uranium projects located in the states of Arizona, Colorado, New Mexico, Texas, and Wyoming, in addition to in the Republic of Paraguay.
Shares of AbbVie Inc. (NYSE:ABBV), inclined 1.37% to $70.43, during its current trading session.
On June 15, Galapagos NV declared a joint presentation with AbbVie Inc., at the 38th annual European Cystic Fibrosis Society conference in Brussels, Belgium.
“Development of Trafficking Assays to Evaluate Novel Corrector-Potentiator Combinations,” presented by Dr Corina Balut of AbbVie, revealed for the first time new assays developed by Galapagos and AbbVie to evaluate the impact of corrector molecules on the rescue of CFTR-F508del and to gain insight into the influence of each component in combination cocktails. Among these was the combination of AVI-tagged CFTR with an MSD discovery platform to provide a more specific and sensitive approach in studying the endocytosis and degradation rate of plasma membrane CFTR. This particular new assay also characterizes the effect of various correctors on channel stability at the cell surface and its endocytosis/recycling, allowing for a better understanding of the mechanism of action of compounds.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Finally, NetApp, Inc. (NASDAQ:NTAP), gained 0.97%, and is now trading at $34.26.
NetApp, and UBS will hold a tech talk to talk about NetApp’s technology, strategy and direction with George Kurian, chief executive officer.
Date: Wednesday, June 24, 2015, Time: 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time.
NetApp, Inc. provides software, systems, and services to manage and store computer data worldwide. It offers Data ONTAP storage operating system that delivers integrated data protection, comprehensive data administration, and built-in software for virtualized, shared infrastructures, cloud computing, and mixed workload business applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
